In:
American Journal of Clinical Oncology, Ovid Technologies (Wolters Kluwer Health), Vol. 43, No. 1 ( 2020-01), p. 1-8
Abstract:
Studies have demonstrated that genetic variants in the miRNA-coding genes might be associated with cancer susceptibility and survival. Here, we aimed to investigate the influence of MIR3142HG single-nucleotide polymorphisms on the individual’s susceptibility to and patients’ prognosis of glioma. Materials and Methods: Six variants were genotyped by Agena MassARRAY iPLEX Gold assay among 529 glioma patients and 502 healthy controls. Association of MIR3142HG polymorphisms with the risk for and prognosis of glioma was analyzed by logistic regression analysis and Cox proportional hazards model, respectively. Results: In the risk analysis, rs17057846 (odds ratio [OR]=1.93, P =0.047), rs2961920 (OR=1.53, P =0.019), and rs58747524 (OR=1.23, P =0.046) polymorphisms were associated with increased glioma risk, while rs7727115 (OR=0.76, P =0.030) and rs1582417 (female individuals, OR=0.49, P =0.017) variants were associated with decreased risk. In the survival analysis, rs1582417 polymorphism (hazard ratio=1.26, P =0.017) contributed to poorer prognosis overall. Rs17057846, rs1582417, and rs2431689 polymorphisms were associated with prognosis of astrocytoma, and rs1582417, rs17057846, and rs58747524 variants were associated with the survival rate in patients with low-grade glioma (I to II). Conclusion: Our study provided the first evidence for the impact of rs1582417, rs17057846, rs2431689, rs2961920, rs58747524, and rs7727115 polymorphisms in MIR3142HG on the susceptibility to and/or prognosis of glioma in the Chinese Han population.
Type of Medium:
Online Resource
ISSN:
0277-3732
DOI:
10.1097/COC.0000000000000587
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2020
detail.hit.zdb_id:
604536-4
Permalink